GeneDx Shares Crash 45% on Q1 Revenue Miss and Lowered Guidance

GeneDx shares plummeted 45% following disappointing Q1 results and a downward revision of its full-year guidance. The broader sector saw further weakness as TransMedics (TMDX) shares fell after reporting Q1 earnings and revenue misses compounded by margin pressure. Similarly, Bio-Techne (TECH) stock declined following misses on both top and bottom lines for the third quarter, despite showing some resilience in operating margins. These combined results have intensified concerns regarding growth trajectories within the healthcare and biotech space. Analysts noted that the combination of missed estimates and guidance cuts across these firms has significantly dampened investor sentiment. The market remains focused on how these companies will manage cost pressures moving forward.